Abatacept (Orencia®)
Subcutaneous Abatacept (Orencia®) in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.
Rapid Review
| Commenced | Completed | Outcome |
| 28/11/2012 | 21/12/2012 | Full Pharmacoeconomic Assessment Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 02/07/2013 | 11/11/2013 | Reimbursement not recommended at the submitted price |
November 2015
The HSE has approved reimbursement following confidential price negotiations.